📇 Rhumatologue · PARIS · (75) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Référence presse grand public
Cité 20 fois dans les médias — pédagogie reconnue
Expérience confirmée
36 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
36ans d'exercice (thèse 1990)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
14
14 articles ont été cités au moins 14fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
853
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
73
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
15
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Sanofi (France)
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Multicentric data challenge for artificial intelligence-based classification of leukocytes: results from the CytologIA consortium
2026Articlenpj Precision Oncology
Joint modeling of tumor dynamics and progression‐free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I–II trials
2024ArticleCPT: Pharmacometrics and Systems Pharmacology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
IMAGERIE MEDICALE JULES JOFFRIN
17 RUE DE TRETAIGNE, 75018 PARIS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 MSN · 20/05/2026
<a href="https://news.google.com/rss/articles/CBMiqAJBVV95cUxNd0o2LUhDUVRoMzcxbFA2S3ZaMTRQSGhkeEtvT1ZvNV9maEpoaC0zUUxsdkwxdmVNTUJ5eVF6Ql8zeGNIZjZIWUg2ZnNveU9JOGQyVjV4cHhOS2JFOEplTElCcXl2R2NvXzZTaUNFaTRWTUNMTElwWWxYdWZMS3dMdS1WUlBDdWhIY3FwVlBVcXROeEFJYVhfOFZ6Z2JLSy0taENpZUhucEdyUjNDWm55TWxPSDVzVFNDVl
📰 MSN · 19/05/2026
<a href="https://news.google.com/rss/articles/CBMi-wFBVV95cUxQd2htbnJ0WVdtMUpQQnNKU0NXRVJVVjl0bmhVMmVtUTdhYWR4Ym9Cc3pRT3pseGhKZkp1WlhIeDROWHM3aWlwVTN3c1J2WEFhQ2tvdWxqWmgxcnlaWHJYQ1Z6dlNSdDJJbzNLblRLSjlmOXluQkxmYTJrN241emlsdkI4SVl4YlQtdlBGSkJ0RXBYM3BPTlRxT3luV0dPeXVpTDNRby1QdGRRVkhYWlZ0YXlSMUUxVWF6WX
📰 MSN · 19/05/2026
<a href="https://news.google.com/rss/articles/CBMi4wJBVV95cUxPSVZwcjRLU2s0QlpDbW53azBHNmVtZGJvSnlFUlVxQmZxMGFOUXVmSkpaMmFnWkp2RnYxRmZIbW9XZWRqblhNejRJN3VtWFl0TTBVUVY5eDNqdzZvUHpLTUlBdWN4dFlqNW9fZ2ZDOXRYU0x1Ymh6aTRKVlZRc2YyYy14R0JpSmFvbV9mNWM2T2FqZUFhQzlaa2lsMGRoQmNlT0MyaVIwM25wTnY5cW0yaXRXRHlMZ0xxNT
📰 MSN · 19/05/2026
<a href="https://news.google.com/rss/articles/CBMinwNBVV95cUxNaFUyZkxsRkFRUFVFaFJVX3BpQTZhU0JKTGVzQjVRMDFTOVRjMUhYWVZfVVBYY3JQeS16Nk94Q1lkVDg4U0cyTW5MSjZzLVdRbXdxOVZuSXRtY2JRdDhkRnk5Z2tTRVhGajkzZHlhdThydnpJZ09IaDR0ZUpMeDMtemFEQVdQQ2wyLTVrY1VzdUJtX3MwZk5sWWJOb3k5ZlI1Zm5JUVkwX3B2YUwwODBhdnRzSllKN2cyUV
📰 MSN · 01/05/2026
<a href="https://news.google.com/rss/articles/CBMisANBVV95cUxQY0ZqdG1mckJQZGVNUzRnYjkwVmY3TlJ4Ri1ueEtUNmFVR3EyV0NYX1hCeVZVQmdSU3M1Yi1xYk1hZVpwVG82UXBoQnprQkc1Qm9POTFCc1FtRDJ5MmZaX1dGWERSaFVHazBzMi0xWUxBSXVsUEFyYlhfUDRzaDNaSHY4NVV3RHJyNzJyY2p2Q2pMcW9OM2EwYTRCRWtXQ2VFaFJuNFU4UFZOTEVrMDFFNW5BMzJoZHRBMU
📰 Télé 7 Jours · 08/01/2026
<a href="https://news.google.com/rss/articles/CBMiiwJBVV95cUxPUk1vRG4zZDRlQWpGc1pMR3FuLTcwWXFjUGV1aTlGa3JNZVRJYjVIYlRvaldyVjlJQ1F6ZXpiSDNpV0RRSnYza1ZwalAxX3ZoLTZIZnNaUnZkWDAtUVhjb0xwZXZSUDhyWUlmUGRja2ZnVmtRZ05FeGRtYVl4UzY1RU5DMnc2cmJtYllBQk1BTHp5X3NFLUVmdFBPb2N1cWMtTS1ZaWEyLXRtRWhwQllqRUdsYV9ibTd6cm
📰 Radio France · 25/09/2025
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNUDVhMzFiVlQwX3M2M2pvZFdtX3l3ZGxZdDZrM3VhYjZvYm8wdlRIX1VNWHRsNzVrVUIyLTQtRUswbjlMaHlhMEhsNGVEVkc2ZW9xTzJ2YWF3NG5Hd3ZweUNxaktmc2hNb0xYR3pwZ2pSUXNGUEhnaGxXWEZsSDVDa0pHcndEbF9sd3hUNGtCX1NMYmd4cVFHazdXNF9VRlhOajdjZm5JRVdGOVJ5YXVFRUE4Rml4LWVoSX
📰 Radio France · 24/04/2025
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNUi04WDR5dXVmS0Z1U2IzS3lTbTRuM25xWG5JSlVMN2dWcjRhRjFYUE5YVkt2dDIyb3d1QXd0djk3MF9sbHZGQ016dVhUZHRrWl91cDRnM291Rkd5S01xOFB6aGtjWnhXdDBUQkZZYjNsdUZleDd5RGZjNHQzLTR1TGt4Y1RNX005czFCcnJPVG9sRjU3UkdBdFVnVUc4ZEw4WGdCR3ZNbFgxeUE1VHYySUlSbGo?oc=5"
📰 Télé Star · 06/06/2024
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOWnlPMVZMd2pfMTRrTV9wbmpIMm5rQ0taZ3FDWDEyOFFYSGdDS0l2ZERWQ0s0N2FBbHdPNktYamtocVZ0VlIwcUY5azBhSzNSeVBMS1g2cHJNVG4zelYwc1pJenBPWVp3NUVDbTk3ZEtjZ2xSQURGajJFZ1dHY1Z4amFsbjI1NFJvM2hPNkh6Y3FWVjZYSzR3YWJNVFllVTgtUFQ3MG9LRHFEQUdZ?oc=5" target="_bl
📰 programme-tv.net · 23/05/2024
<a href="https://news.google.com/rss/articles/CBMi-wFBVV95cUxQT0prb1J1RDFZUFBWQWR4ZUhTMVlNclVySjZHRjQ2Q2lfbFJoQTdGb3FQa29sWUdVWGFWYndMbUxwT09wVWpjMGhNcjNORUdtQ2dXY2xJc204clR2RWUxQ19pUzJYbzFSX3ZJWWVYR191MjRXcXFTbFlGNTZ2RlZtOTQ5Mzh6aGIyZU5rWndycGlPRmswZVc3V3ZkaTFtb3JpdXZKbktTUDg0S3ZrdlVlQjl5ZzgteTZWdH
📰 Télé Star · 03/07/2023
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQb2xIVXJmS3VHVVVEU0dwdWF4bV9JbWFmX3BUaWpsOTRBcEtBYlJvbkNPSGVXY2VqODdTajc2ODdGaDZNUjI4aEtuZktwU1dNNnJ4RnZpbXRhSzlnWDVoZlQzQWV1ZlFHUTgyaVl2NDFFWk9nczV6TjhkV3N1REdaejJXZ3JiMUt2LVQzZlIzX1VuTE82X0xCYjdpbVNWNGdwQUN3akVmNDhUamdkeFRrOHV3?oc=5" tar
📰 programme-tv.net · 14/06/2022
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxQV0JWSEJpdVFCeDd2NW5sV0JVQmVMeWFYQnYzRlpOck1yMUwtUVZGVUpLM2dvc0c1VENLV1JobG11bkxWNVFjRm9wVVRWaFU0OHhiejBfSHpjU3IzUHNVSnh4clhOWEluQ2dySEhEeDBWRHlRdUVlZF8tcTBPXzU4M2toaXZxQ2lqcWZpWmpfYTVoMlEwSlRVWUJMYVZtNFdTSFZWbTVMcXVyeXZ4WWFlY0VLbjJOc1VDM2
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
PURPOSE Amcenestrant (oral selective estrogen receptor degrader) demonstrated promising safety and efficacy in earlier clinical studies for endocrine-resistant, estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (aBC). PATIENTS AND METHODS In AMEERA-3 (ClinicalTrials.gov identifier: NCT04059484 ), an open-label, worldwide phase II trial, patients with ER+/HER2– aBC who progressed in the (neo)adjuvant or advanced settings after not more than two previous lines of endocrine therapy (ET) were randomly assigned 1:1 to amcenestrant or single-agent endocrine treatment of physician's choice (TPC), stratified by the presence/absence of visceral metastases, previous/no treatment with cyclin-dependent kinase 4/6 inhibitor, and Eastern Cooperative Oncology Group performance status (0/1). The primary end point was progression-free survival (PFS) by independent central review, compared using a stratified log-rank test (one-sided type I error rate of 2.5%). RESULTS Between October 22, 2019, and February 15, 2021, 290 patients were randomly assigned to amcenestrant (n = 143) or TPC (n = 147). PFS was numerically similar between amcenestrant and TPC (median PFS [mPFS], 3.6 v 3.7 months; stratified hazard ratio [HR], 1.051 [95% CI, 0.789 to 1.4]; one-sided P = .643). Among patients with baseline mutated ESR1; (n = 120 of 280), amcenestrant numerically prolonged PFS versus TPC (mPFS, 3.7 v 2.0 months; stratified HR, 0.9 [95% CI, 0.565 to 1.435]). Overall survival data were immature but numerically similar between groups (HR, 0.913; 95% CI, 0.595 to 1.403). In amcenestrant versus TPC groups, treatment-emergent adverse events (any grade) occurred in 82.5% versus 76.2% of patients and grade ≥3 events occurred in 21.7% versus 15.6%. CONCLUSION AMEERA-3 did not meet its primary objective of improved PFS with amcenestrant versus TPC although a numerical improvement in PFS was observed in patients with baseline ESR1 mutation. Efficacy and safety with amcenestrant were consistent with the standard of care for second-/third-line ET for ER+/HER2– aBC.
Annals of the rheumatic diseases · 2023
Nature communications · 2022
AbstractAMEERA-1 is a Phase 1/2 open-label single-arm study evaluating once-daily (QD) amcenestrant, an orally bioavailable selective estrogen receptor (ER) degrader, in postmenopausal women with ER+/HER2− advanced breast cancer (NCT03284957), who were mostly heavily pretreated (including targeted therapies and fulvestrant). In the dose escalation phase (Part A: n = 16), patients received amcenestrant 20-600 mg QD. Based on absence of dose-limiting toxicities, paired functional 18F-fluoroestradiol positron emission tomography, and pharmacokinetics, 400 mg QD was selected as recommended Phase 2 dose (RP2D) for the dose expansion phase (Part B: n = 49). No Grade ≥3 treatment-related adverse events or clinically significant cardiac/eye toxicities were reported. The Part B primary endpoint, confirmed objective response rate (ORR) was 3/45 at the interim analysis and 5/46 (10.9%) at the final analysis. The overall clinical benefit rate (CBR) was 13/46 (28.3%). CBRs among patients with baseline wild-type and mutated ESR1 were 9/26 (34.6%) and 4/19 (21.1%), respectively. Paired tumor biopsy and cell-free DNA analyses revealed ER inhibition and degradation, and a reduction in detectable ESR1 mutations, including Y537S. In conclusion, amcenestrant at RP2D of 400 mg QD for monotherapy is well-tolerated with no dose-limiting toxicities, and demonstrates preliminary antitumor activity irrespective of baseline ESR1 mutation status.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
International journal of laboratory hematology · 2026 · Journal Article
Soulard M, Ketatni H, Croix P, Wuilleme S, et al.
Cureus · 2026 · Case Reports
Ali S, Memari K, Boutros J, Williams S, et al.
La Revue de medecine interne · 2026 · Journal Article
Grange L, Chaigne B, Casadevall M, Cohen P, et al.
RMD open · 2025 · Journal Article
Iudici M, Salis Z, Cohen P, Néel A, et al.
Cureus · 2025 · Case Reports
Ali S, Banda A, Ramirez-Matos C, Cohen P
Current opinion in immunology · 2025 · Journal Article
Clement TL, Cohen PL
Rheumatology (Oxford, England) · 2025 · Journal Article
Maillet F, Nguyen Y, Espitia O, Perard L, et al.
Journal of clinical medicine · 2024 · Journal Article
Soulard M, Ketatni H, Visseaux C, Croix P, et al.
Nature communications · 2024 · Journal Article
Li Z, Shi B, Li N, Sun J, et al.
Seminars in arthritis and rheumatism · 2024 · Journal Article
Boukhlal S, Chouchana L, Saadi M, Casadevall M, et al.
Journal of autoimmunity · 2024 · Journal Article
Chevalier K, Chassagnon G, Leonard-Louis S, Cohen P, et al.
CPT: pharmacometrics & systems pharmacology · 2024 · Journal Article
Cerou M, Thai HT, Deyme L, Fliscounakis-Huynh S, et al.
Annals of the rheumatic diseases · 2024 · Journal Article
Cohen P, Ziff D, Lipsky PE
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · Journal Article
Tolaney SM, De Kermadec E, Cohen P, Paux G, et al.
Annals of the rheumatic diseases · 2023 · Multicenter Study
Molina B, Padoan R, Urban ML, Novikov P, et al.
Rheumatology (Oxford, England) · 2023 · Journal Article
Sorin B, Iudici M, Guerry MJ, Samson M, et al.
Revue des maladies respiratoires · 2023 · Observational Study
Akdime F, Habib S, Regard L, Terrier B, et al.
Journal of autoimmunity · 2023 · Journal Article
Rohmer J, Nguyen Y, Trefond L, Agard C, et al.
Archives of dermatological research · 2023 · Journal Article
Karim M, Boikess RS, Schwartz RA, Cohen PJ
Frontiers in immunology · 2023 · Editorial
Zizzo G, Cohen PL
RMD open · 2023 · Journal Article
Samson M, Devilliers H, Thietart S, Charles P, et al.
Lupus science & medicine · 2023 · Journal Article
Petrova T, Figueras-Vadillo C, Nanda SK, Scudamore C, et al.
International journal of laboratory hematology · 2023 · Journal Article
Soulard M, Croix P, Cohen P
Research square · 2023 · Preprint
Greenblatt M, Debnath S, Yallowitz A, McCormick J, et al.
Nature communications · 2022 · Clinical Trial, Phase I
Bardia A, Chandarlapaty S, Linden HM, Ulaner GA, et al.
Diagnostics (Basel, Switzerland) · 2022 · Journal Article
Tieu A, Chaigne B, Dunogué B, Dion J, et al.
Cureus · 2021 · Case Reports
Cohen PR
EBioMedicine · 2025 · Journal Article
Pasquiers B, Blanchet B, Puéchal X, Declèves X, et al.
Annals of the rheumatic diseases · 2024 · Journal Article
Delestre F, Charles P, Karras A, Pagnoux C, et al.
Journal of autoimmunity · 2024 · Journal Article
Liberatore J, Nguyen Y, Hadjadj J, Cohen P, et al.
EBioMedicine · 2025 · Journal Article
Pasquiers B, Blanchet B, Puéchal X, Declèves X, et al.
Annals of the rheumatic diseases · 2024 · Journal Article
Delestre F, Charles P, Karras A, Pagnoux C, et al.
JAMA network open · 2022 · Observational Study
Puéchal X, Iudici M, Perrodeau E, Bonnotte B, et al.
Seminars in arthritis and rheumatism · 2026 · Journal Article
Chevalier K, Bader-Meunier B, Kone-Paut I, Thoreau B, et al.
RMD open · 2025 · Journal Article
Chevalier K, Thoreau B, Michel M, Godeau B, et al.
Journal of internal medicine · 2024 · Journal Article
Chevalier K, Thoreau B, Michel M, Godeau B, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · Journal Article
Cortés J, Hurvitz SA, O'Shaughnessy J, Delaloge S, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · Randomized Controlled Trial
Tolaney SM, Chan A, Petrakova K, Delaloge S, et al.
Cureus · 2024 · Case Reports
Cohen PR
Cureus · 2024 · Case Reports
Cohen PR
Arthritis care & research · 2023 · Journal Article
Delvino P, Sardanelli F, Monti S, Cohen P, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Iudici M, Pagnoux C, Courvoisier DS, Cohen P, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Sorin B, Samson M, Durel CA, Diot E, et al.
Cureus · 2025 · Case Reports
Cohen PR
NPJ precision oncology · 2026 · Journal Article
Sourdeau E, Geneviève F, Baseggio L, Badaoui B, et al.
Cancer reports (Hoboken, N.J.) · 2025 · Journal Article
Ayres C, Burbidge H, Garratt J, Mohan GR, et al.
Cureus · 2023 · Case Reports
Cohen PR
Diagnostic and interventional imaging · 2024 · Journal Article
de Frémont GM, Monaya A, Chassagnon G, Bouam S, et al.
Two Patient Studies of a Companion Diagnostic Immuno-Positron Emission Tomography (PET) Tracer for Measuring Human CA6 Expression in Cancer for Antibody Drug Conjugate (ADC) Therapy
An antigen binding fragment (BFab) derived from a tumor-associated mucin 1–sialoglycotope antigen (CA6) targeting antibody (huDS6) was engineered. We synthesized a companion diagnostic positron emission tomography (PET)
Two Patient Studies of a Companion Diagnostic Immuno-Positron Emission Tomography (PET) Tracer for Measuring Human CA6 Expression in Cancer for Antibody Drug Conjugate (ADC) Therapy
An antigen binding fragment (BFab) derived from a tumor-associated mucin 1–sialoglycotope antigen (CA6) targeting antibody (huDS6) was engineered. We synthesized a companion diagnostic positron emission tomography (PET)
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib <i>versus</i> letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer
Background:For estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC), the current standard first-line treatment includes an aromatase inhibitor in combina
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib <i>versus</i> letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer
Background:For estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC), the current standard first-line treatment includes an aromatase inhibitor in combina
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Rheumatology (Oxford, England) · 2022 · Journal Article
Sartorelli S, Chassagnon G, Cohen P, Dunogué B, et al.
RMD open · 2022 · Comparative Study
Puéchal X, Iudici M, Pagnoux C, Cohen P, et al.
Journal of internal medicine · 2022 · Journal Article
Thietart S, Beinse G, Smets P, Karras A, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Sorin B, Samson M, Durel CA, Diot E, et al.
Therapeutic advances in medical oncology · 2022 · Journal Article
Bardia A, Cortes J, Hurvitz SA, Delaloge S, et al.